High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 112-117

  Borgfeldt, Christer ^a   Bendahl, Pär Ola ^a   Fernö, Mårten ^a   Casslén, Bertil ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Human, Prognosis; Ovarian neoplasm; Survival analyses; tPA

Indexed keywords

BIOLOGICAL MARKER; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

EID: 0141817889     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00493-1     Document Type: Article

References (41)

1. Cancer incidence in Sweden 1998, 4. 2000;1-155 The National Board of Health and Welfare, Centre for Epidemiology, Stockholm, Sweden.
2. Pecorelli S., Benedet J., Beller U., Creasman W., Heintz A., Pettersson F. FIGO annual report on the results of treatment in gynaecological cancer, 61. 2001;1-184 Isis Medical Media Ltd. Oxford, England.
3. Taylor K.J., Schwartz P.E. Screening for early ovarian cancer. Radiology. 192:(1):1994;1-10.
4. Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T., Halvorsen T., et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 103:(8):1996;826-831.
5. Zanetta G., Rota S., Lissoni A., Meni A., Brancatelli G., Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 81:(1):2001;63-66.
6. Woolas R.P., Xu F.J., Jacobs I.J., Yu Y.H., Daly L., Berchuck A., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 85:(21):1993;1748-1751.
7. Hakama M., Stenman U.H., Knekt P., Jarvisalo J., Hakulinen T., Maatela J., et al. CA 125 as a screening test for ovarian cancer. J Med Screen. 3:(1):1996;40-42.
8. Jacobs I.J., Skates S., Davies A.P., Woolas R.P., Jeyerajah A., Weidemann P., et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration a prospective cohort study . BMJ. 313:(7069):1996;1355-1358.
9. Rosenthal A.N., Jacobs I.J. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers. 13:(4):1998;216-220.
10. Morgante G., la Marca A., Ditto A., De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol. 106:(6):1999;524-527.
11. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis a review . Int J Cancer. 72:(1):1997;1-22.
12. Borgfeldt C., Casslen B., Liu C.L., Hansson S., Lecander I., Astedt B. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer. 79:1998;588-595.
13. Casslen B., Gustavsson B., Astedt B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer. 27:(11):1991;1445-1448.
14. Duffy M.J. Proteases as prognostic markers in cancer. Clin Cancer Res. 2:1996;613-618.
15. de Witte J.H., Sweep C.G., Klijn J.G., Grebenschikov N., Peters H.A., Look M.P., et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer. 79:(7-8):1999;1190-1198.
16. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60:(3):2000;636-643.
17. Ho C.H., Yuan C.C., Liu S.M. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol. 75:(3):1999;397-400.
18. Stephens R.W., Nielsen H.J., Christensen I.J., Thorlacius-Ussing O., Sorensen S., Dano K., et al. Plasma urokinase receptor levels in patients with colorectal cancer relationship to prognosis . J Natl Cancer Inst. 91:(10):1999;869-874.
19. Fernebro E., Madsen R.R., Ferno M., Brunner N., Bendahl P., Christensen I.J., et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer. 37:(4):2001;486-491.
20. Nielsen H.J., Pappot H., Christensen I.J., Brunner N., Thorlacius-Ussing O., Moesgaard F., et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ. 316:(7134):1998;829-830.
21. Riisbro R., Stephens R.W., Brunner N., Christensen I.J., Nielsen H.J., Heilmann L., et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol. 82:(3):2001;523-531.
22. Hart D.A., Rehemtulla A. Plasminogen activators and their inhibitors regulators of extracellular proteolysis and cell function . Comp Biochem Physiol B. 90:(4):1988;691-708.
23. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 73:(1):1993;161-195.
24. Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., Lijnen H.R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 48:(5):1988;1348-1349.
25. Kim S.J., Shiba E., Kobayashi T., Yayoi E., Furukawa J., Takatsuka Y., et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer a prospective study on multicenter basis . Clin Cancer Res. 4:(1):1998;177-182.
26. de Witte J.H., Sweep C.G., Klijn J.G., Grebenschikov N., Peters H.A., Look M.P., et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer. 80:(1,2):1999;286-294.
27. Casslen B., Bossmar T., Lecander I., Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer. 30A:(9):1994;1302-1309.
28. Kalyan N.K., Lee S.G., Wilhelm J., Fu K.P., Hum W.T., Rappaport R., et al. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem. 263:(8):1988;3971-3978.
29. Mussoni L., Conforti G., Gambacorti-Passerini C., Alessio G., Pepe S., Vaghi M., et al. Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. Eur J Cancer Clin Oncol. 22:(4):1986;373-380.
30. Zacharski L.R., Memoli V.A., Ornstein D.L., Rousseau S.M., Kisiel W., Kudryk B.J. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst. 85:(15):1993;1225-1230.
31. Anstey J.T., Blythe J.G. Fibrin degradation products and the diagnosis of ovarian carcinoma. Obstet Gynecol. 52:(5):1978;605-608.
32. Maggino T., Paternoster D., Valente S., Marchetti M., Marchesoni D., Menighetti M., et al. Fibrinolysis in ovarian cancer. Eur J Gynaecol Oncol. 2:(2):1981;70-72.
33. Paternoster D., Maggino T., Valente S., Paternoster A., Pengo V., Marchesoni D. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer. Clin Exp Obstet Gynecol. 8:(2):1981;64-65.
34. Bacon-Baguley T., Ogilvie M.L., Gartner T.K., Walz D.A. Thrombospondin binding to specific sequences within the A alpha-and B beta-chains of fibrinogen. J Biol Chem. 265:(4):1990;2317-2323.
35. Hafter R., Klaubert W., Gollwitzer R., von Hugo R., Graeff H. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Res. 35:(1):1984;53-64.
36. Zafar R.S., Zeng Z., Walz D.A. Localization of two binding domains for thrombospondin within fibronectin. Arch Biochem Biophys. 297:(2):1992;271-276.
37. Raigoso P., Junco A., Andicoechea A., Gonzalez A., Garcia-Muniz J.L., Allende M.T., et al. Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa relationship with clinicopathologic parameters and prognostic significance . Int J Biol Markers. 15:(1):2000;44-50.
38. Ferrier C.M., Suciu S., van Geloof W.L., Straatman H., Eggermont A.M., Koops H.S., et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer. 83:(10):2000;1351-1359.
39. Pavey S.J., Hawson G.A., Marsh N.A. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 12:(1):2001;51-58.
40. Hart P.H., Vitti G.F., Burgess D.R., Singleton D.K., Hamilton J.A. Human monocytes can produce tissue-type plasminogen activator. J Exp Med. 169:(4):1989;1509-1514.
41. Moser T.L., Young T.N., Rodriguez G.C., Pizzo S.V., Bast R.C. Jr, Stack M.S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer. 56:(4):1994;552-559.